Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Weighted Average) (2016 - 2025)

United Therapeutics (UTHR) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $44.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 1.99% to $44.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.3 million through Dec 2025, down 1.99% year-over-year, with the annual reading at $44.3 million for FY2025, 1.99% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $44.3 million in Q4 2025 for United Therapeutics, up from $43.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $47.0 million in Q1 2024 to a low of $43.8 million in Q3 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $45.4 million across 5 years, with a median of $45.2 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 3.53% in 2023 and later fell 4.47% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $44.9 million in 2021, then increased by 1.34% to $45.5 million in 2022, then grew by 2.86% to $46.8 million in 2023, then fell by 3.42% to $45.2 million in 2024, then decreased by 1.99% to $44.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for UTHR at $44.3 million in Q4 2025, $43.8 million in Q3 2025, and $45.0 million in Q2 2025.